Erythropoesis Stimulating Agents — CPB 0195 | AETNA Coverage Update

Aetna modified CPB 0195 covering erythropoiesis stimulating agents (ESAs), effective January 22, 2026. Here's what billing teams need to do.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0195 governing ESA coverage — including Aranesp, Epogen, Procrit, Retacrit, and Mircera — for commercial medical plans. The updated coverage policy adds new coverage criteria for myelofibrosis-associated anemia and anemia in cancer patients undergoing palliative treatment. Primary HCPCS codes affected include J0881, J0882, J0885, J0887, J0888, Q4081, Q5105, and Q5106. If your team handles ESA billing across oncology, nephrology, or hematology, this update changes how you document medical necessity before submitting claims.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Erythropoiesis Stimulating Agents — CPB 0195
Policy Code	CPB 0195
Change Type	Modified
Effective Date	January 22, 2026
Impact Level	High
Specialties Affected	Oncology, Nephrology, Hematology, Infectious Disease, Surgery
Key Action	Audit precertification workflows and iron store documentation before submitting any ESA claim under the updated CPB 0195 Aetna criteria

---

Aetna Erythropoiesis Stimulating Agent Coverage Criteria and Medical Necessity Requirements 2026

The Aetna ESA coverage policy under CPB 0195 Aetna system requires precertification for all participating providers and members in applicable plan designs. Before you submit a single claim, call (866) 752-7021 or fax (888) 267-3277 to get that prior authorization in place. No precertification means no reimbursement — full stop.

Before any ESA therapy begins, every member must have iron deficiency anemia assessed and adequate iron stores confirmed. Specifically, the policy requires a serum transferrin saturation (TSAT) level of at least 20% within the prior three months — or documented active iron therapy. This isn't a soft recommendation. It's a hard stop for both initial approval and continuation of therapy.

Members may not use Epogen, Procrit, or Retacrit alongside other ESAs or with hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). If your patient is on daprodustat (J0889) or vadadustat (J0901), they cannot concurrently bill ESAs. Flag that in your charge capture now.

Epoetin Alfa (Epogen/Procrit) and Epoetin Alfa-Epbx (Retacrit) — Initial Approval Criteria

Aetna considers epoetin alfa (J0885, Q4081) and epoetin alfa-epbx/Retacrit (Q5105, Q5106) medically necessary for the following indications. Pretreatment hemoglobin requirements exclude values from recent transfusions — document that clearly in the record.

Covered indications require pretreatment hemoglobin less than 10 g/dL for most diagnoses:

Two indications carry a different hemoglobin threshold:

#	Covered Indication Copy
1	Reduction of allogeneic red blood cell transfusion before elective, noncardiac, nonvascular surgery — pretreatment hemoglobin ≤ 13 g/dL
2	Anemia due to cancer in members undergoing palliative treatment — no explicit hemoglobin floor listed, but medical necessity documentation is still required

That last one — anemia due to cancer in palliative treatment — is notable. Palliative care documentation must clearly support the indication, or you'll see a claim denial.

Continuation of Therapy Thresholds

Continuation criteria use current hemoglobin, not pretreatment hemoglobin. The TSAT iron store requirement applies here too.

#	Covered Indication Copy
1	CKD: current hemoglobin < 12 g/dL
2	Myelosuppressive chemotherapy: documented in policy (see full CPB for complete continuation criteria)

The gap between < 10 g/dL for initiation and < 12 g/dL for continuation of CKD therapy is intentional. Your clinical documentation must track which phase of therapy the claim represents. Mixing up initiation and continuation hemoglobin thresholds is a fast path to denial.

Darbepoetin Alfa (Aranesp) — J0881 and J0882

Darbepoetin alfa follows similar coverage logic. J0881 covers non-ESRD use; J0882 covers ESRD on dialysis. The same precertification requirement applies. Verify your practice is routing Aranesp claims through the same prior authorization workflow as epoetin alfa claims — they fall under the same CPB 0195 Aetna precertification umbrella.

Mircera — Epoetin Beta (J0887, J0888)

Epoetin beta (Mircera) is also covered under this policy when selection criteria are met. J0887 is for ESRD on dialysis; J0888 is for non-ESRD use. These carry the same iron store and precertification requirements.

---

Aetna ESA Exclusions and Non-Covered Indications

Aetna's updated coverage policy draws a hard line around bone marrow and stem cell services. CPT codes 38204 through 38232 — covering the full range of bone marrow and stem cell harvest, processing, and preparation procedures — are explicitly not covered for the indications listed in CPB 0195.

Transplantation and post-transplantation cellular infusion codes 38240, 38241, 38242, and 38243 are also not covered under this bulletin.

On the HCPCS side, peginesatide (J0890) is not covered. This agent was withdrawn from the U.S. market, so billing J0890 would be incorrect regardless — but the explicit exclusion signals Aetna is keeping it listed for denial purposes if anyone attempts it.

Cord blood and stem cell transplantation codes S2140, S2142, and S2150 round out the not-covered list. If your team is managing patients who receive both ESA therapy and transplantation services, those transplant-related claims need to travel on different claim lines with clear separation in documentation.

Aetna considers all ESA indications not listed above as experimental, investigational, or unproven. That catch-all matters for off-label use. If a provider is prescribing an ESA for anything not on the approved indication list, expect a denial without a strong appeal backed by clinical literature.

---

Coverage Indications at a Glance

---

Aetna ESA Billing Guidelines and Action Items 2026

The effective date of January 22, 2026 means this policy is already live. If you haven't audited your workflows against the updated CPB 0195 criteria, do it now.

Copy Action Items

If your patient population includes oncology or nephrology cases with complex co-treatments, talk to your compliance officer before the effective date has caused a backlog of denials. The interaction between ESA coverage rules and transplant exclusions is where most billing errors will cluster.

---

CPT, HCPCS, and ICD-10 Codes for Erythropoiesis Stimulating Agents Under CPB 0195

HCPCS Codes Covered When Selection Criteria Are Met

Not Covered / Experimental Codes

Other CPT Codes Related to CPB 0195

These codes are related to ESA administration and appear in the policy. Coverage depends on the underlying indication and whether the ESA itself is approved.

Other HCPCS Codes Related to CPB 0195

Key ICD-10-CM Diagnosis Codes

The full policy lists 436 ICD-10-CM codes. Sample codes from the published policy data include:

The complete ICD-10 code list spans 436 codes covering CKD, MDS, malignancies, HIV-related conditions, and surgical anemia indications. Pull the full list from the CPB 0195 source document to build your charge capture edits.

---